A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
|Articles|March 12, 2013
Supplements and Featured Publications
- Managing Costs in High-Risk Obstetrics
Managing Costs in High-Risk Obstetrics
Author(s)Maria Lopes, MD, MS
Advertisement
Premature birth is responsible for an estimated $26 billion in costs to the American healthcare system annually, with high-risk pregnancies constituting a major category of high cost. Spontaneous preterm births due to preterm labor or preterm premature rupture of membranes represent the majority of all preterm births. This article identifies ways in which new technology can improve the diagnostic accuracy of pregnancy-related disorders and assist in managing the costs of high-risk obstetrics.
To access the publication, “Managing Costs in High-Risk Obstetrics,” please click on the image below.
Advertisement
Related to this article
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
Symptom-tracking tools may improve awareness and patient-clinician communication but can also add stress.
Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.
The 2026 COA Payer Exchange and Innovation Summit began with a panel on AI and the ever-changing digital infrastructure in community oncology.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
Longer undetectable hepatitis D RNA on bulevirtide predicts durable suppression off therapy, but rebound and ALT flares rise, especially in cirrhosis.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
3
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
4
Drug Price Drives Value of MASH Therapies More Than Efficacy
5